MAY 3 0 2006 THE TRADELLE

PTO/SE/I/1 A (10-05)

Approved for use through 07/31/2006, OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Paperwork Reduction Act of 1995, no persone are required to respond to a collection of information unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

								ELETION
Title of Invention	TISSUE PF OF SEPSIS	ROTE(THE FORMA	UNES FOR	THE TRI ADHESIO	EATMENT A	AND PREV	ENTION
As the belo	w named inven	tor(s), V	ve declare that					
This declar	ation is directed	to:						
		The a	tached application	, or				i
	. 🗖	Applic	ation No.		filed on):e	applicable);
			As amended on					
I/we believe that I/we am/arc the original and first inventor(s) of the subject matter which is claimed and for which a petent is sought;								
amendme	nt specifically re	ferred to						•
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filling date of the prior application and the national or PCT International filling date of the continuation-in-part application.								
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.								
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.								
FULL NAI	ME OF INVENT	OR(S)						
Inventor o	ne: MICHAEL B	RINES					_	
Signature: Citizen of. US								
inventor to	NO: ANTHONY	CERAMI			-			
Signature						_Citizen of: <u>US</u>		
			spresentative ere bel					
This collection	o of information is r	anulred by	35 U.S.C. 115 and 37	CFR 1.63. The to	ormation is requ	and to obtain or re	tain a benefit by the	public which is to file

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by S5 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gestioning, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, any comments on the smouth of time your require to complete this form antifer suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commissioner. P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, can 1-800-PTO-9199 and select option 2.

PADEMA	error and and and a second or to the	Supplements: She		•	_ 7
DECLARA	T!ON			Fayer	
Name of Additional Joint Inve	entor, if any:	A pention has	s been filed for the	s unsigned inventor	
Zima Alama / Enst and	widen (If any))	Family Name or St	mama.		
:emas		Coleman			
(nventors	_			Dats	
Signature	NY	us		US Clitzenship	
M: Meco Residence: City	State	Coun	ту	Ottoursen	
20 Emery Road					
Mailing Address	1		10549	us	
ML KISCO	NY State		Zip	Country	
City	rentos Many:	A nettion h	as been filed for t	his unsigned invento	of
Name of Additional Joint inv	entor, if any.	A pestalini			
Given Name (first and	middle (if any))		Family Name	or Sumame	
Osman		Ytmez		·	
	2			1	
Inventor's Signature				Date	
Gotter	izmir		TP.	TR.	
Residence: City	State		Соипту	Chiza	nship
100 Soked Keleci, Apt. 24/17					
Mailing Address					
Gottage	bannii .			TR	
City	State		Zip	Country	
Name of Additional Joint In	ventor, if any:	A petition	has been filed for	this unsigned invent	or
		1		e or Sumame	
Given Name (first and	i middle (if anyl)	+	rainty realit	o Ci Camano	
<u>.</u>				· ·	
Inventor's Signature				Dete	
	3	1	Country	Citiz	enship
Residence: City	State		Country		_:

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.83. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 minutes to complete, including asthering, preparing, and automating the completed application form to the USPTO. Time will vary depending upon the individual minutes to complete the form end/or auggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandra, VA 22313-1450.

FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandra, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/81 (01-06)
Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMER the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

ANEWE HEN

Application Number	10/573,905
Filing Date	March 29, 2006
First Named Inventor	Michael Brines
Title	Tissue Protective Cytokines for the
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	WP03-1A04-US

I hereby revoke all previous powers of attorney given in the above-identified application.						
I hereby appoint:						
Practitioners associated with the Customer Number:	61297					
OR						
Practitioner(s) named below:						
Name	Registration Number					
as my/our attorney(s) or agent(s) to prosecute the application identified al Trademark Office connected therewith.	pove, and to transact all business in the United States Patent and					
Please recognize or change the correspondence address for the above-ic	dentified application to:					
The address associated with the above-mentioned Customer No.						
OR						
The address associated with Customer Number:						
OR						
Individual Name	Firm or Individual Name					
Address						
City State Zip						
Country	Ctate					
Telephone	Email					
l am the:						
Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)						
SIGNATURE of Applicant or Assignee of Record						
Signature frede 1. Amble	Date May 30, 2006					
Name Frederick J. Hamble	Telephone (914)762-7586					
Title and Company Corporate Secretary, Warren Pharmaceuticals, Inc.						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						
*Total of forms are submitted.						

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAY 3 0 2006

PTO/SB/96 (12-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)					
Applicant/Patent Owner: YILMAZ, OSMAN					
Application No./Patent No./Control No.: 10/573.905 Filed/Issue Date: March 29. 2006					
Entitled: Tissue Protective Cytokines for the Treatment and Prevention of Sepsis and the Formation of Adhesions					
Warren Pharmaceuticals, Inc.					
(Name of Assignee) states that it is: 1. the assignee of the entire right, title, and interest; or	(Type of Assignee: corporation, partnership, university, government agency, etc.)				
an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is%)					
in the patent application/patent identified above by virtue of either	er:				
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or a true copy of the original assignment is attached.					
OR B. A chain of title from the inventor(s), of the patent application	ion/patent identified above, to the current assignee as follows:				
From: To The document was recorded in the United States F Reel, Frame	Patent and Trademark Office at , or for which a copy thereof is attached.				
2. From: To	: Patent and Trademark Office at				
The document was recorded in the United States I Reel, Frame	aton and Trademark Office at				
3. From:To					
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.					
Additional documents in the chain of title are listed on a supplemental sheet.					
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]					
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.					
frede of Amble	May 30, 2006				
Signature	Date				
Frederick J. Hamble	914-762-7586				
Printed or Typed Name	Telephone Number				
Corporate Secretary, Warren Pharmaceuticals, II Title	<u>nc.</u>				

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

WHEREAS, I, Osman Yilmaz, citizen of Turkey, residing at 100 Sokad Kalaci, Apt. 24/17, Gottepe Izmir Turkey am a coinventor with Michael Brines, citizen of the U.S.A., residing at 1 Wepawaug Road, Woodbridge Connecticut 06525; Anthony Cerami, citizen of the U.S.A., residing at 58a Heritage Hills Road, Somers, New York 10589; Thomas Coleman, citizen of the U.S.A., residing at 20 Emery Street, Mt. Kisco, New York 10549, of the invention in TISSUE PROTECTIVE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS AND THE FORMATION OF ADHESIONS for which we have executed an application for a Patent of the United States

	which is executed on		even date herewith or	
Ø	which is identified by atte	orney o	docket no. 20528.0008.PR	C
Ø	which was filed on Septe	mber 2	9, 2003, Application No. 6	50/506,149

and WHEREAS, Warren Pharmaceuticals, Inc., having an address of 712 Kitchawan Road, Ossining, NY 10562, ASSIGNEE, is desirous of obtaining our entire right, title and interest in, to and under the said invention and the said application:

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) to us in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, we, the said ASSIGNORS, have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said invention, and the said United States application and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;

AND WE HEREBY authorize and request the Commissioner of Patents and Trademarks of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND WE HEREBY covenant and agree that we have full right to convey the entire interest herein assigned, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND WE HEREBY further covenant and agree that we will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEES, their successors, legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries.

IN TESTIMONY WHEREOF, We hereunto set our hands and seals the day and year set opposite our respective signatures.

Date

___L.S.

Nes +

ness

- : -